---
title: "Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296478792.md"
description: "Harrow Inc. announced clinical study results for IHEEZO, an ocular anesthetic gel used during intravitreal injections. The bilateral-eye study found that patients reported 58% less post-injection discomfort with IHEEZO compared to the legacy anesthetic proparacaine. This benefit was consistent across multiple time checks and strongest immediately after injection, supporting its adoption in high-volume retina practices."
datetime: "2026-08-20T11:01:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296478792.md)
  - [en](https://longbridge.com/en/news/296478792.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296478792.md)
generator: "portal-rs"
---

# Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections

-   Harrow reported new clinical study results for IHEEZO, an ocular anesthetic gel used during intravitreal injections. \* Findings were announced now, with no indication of a future conference presentation. \* Patients in a bilateral-eye study reported less post-injection discomfort with IHEEZO versus a commonly used legacy anesthetic. \* Benefit was consistent across multiple post-procedure time checks, strongest soon after injection, supporting broader adoption in high-volume retina practices. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200700PRIMZONEFULLFEED9813296) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)

## Related News & Research

- [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md)
- [Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000](https://longbridge.com/en/news/296149417.md)
- [Homerun Resources signs MOU with Cebrace to explore solar glass partnership in Brazil](https://longbridge.com/en/news/296347626.md)
- [Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients](https://longbridge.com/en/news/296573642.md)
- [The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch | PNGAF Stock News](https://longbridge.com/en/news/296345617.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**